Literatur: Heparin

Als Hinweis auf potentielle weitere Informationsquellen. Kein Anspruch auf Vollständigkeit.

 

Heparin

  • 1. Anderson JL, Adams CD, Antman EM, et al, "2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines," Circulation, 2011, 123(18):e426-579. [PubMed 21444888]
  • 2. Antman EM, Anbe DT, Armstrong PW, et al,“ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction),” Circulation, 2004, 110(9):e82-292. [PubMed 15339869]
  • 3. Antman EM, Hand M, Armstrong PW, et al, “2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,” J Am Coll Cardiol, 2008, 51(2):210-49. [PubMed 18191746]
  • 4. Broderick J, Connolly S, Feldmann E, et al, “Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group,” Stroke, 2007, 38(6):2001-23. Available at stroke.ahajournals.org. [PubMed 17478736]
  • 5. Dager WE and White RH, “Pharmacotherapy of Heparin-Induced Thrombocytopenia,” Expert Opin Pharmacother, 2003, 4(6):919-40. [PubMed 12783589]
  • 6. Flaherty ML, “Anticoagulant-Associated Intracerebral Hemorrhage,” Semin Neuro, 2010, 30(5):565-72. [PubMed 21207349]
  • 7. Francis JL, Groce JB 3rd, and the Heparin Consensus Group, “Challenges in Variation and Response of Unfractionated Heparin,” Pharmacotherapy, 2004, 24(8 Pt 2), 108-19. [PubMed 15334856]
  • 8. Greinacher A, Janssens U, Berg G, et al, “Lepirudin (Recombinant Hirudin) for Parenteral Anticoagulation in Patients With Heparin-Induced Thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) Investigators,” Circulation, 1999, 100(6):587-93. [PubMed 10441094]
  • 9. Greinacher A, Volpel H, Janssens U, et al, “Recombinant Hirudin (Lepirudin) Provides Safe and Effective Anticoagulation in Patients With Heparin-Induced Thrombocytopenia: A Prospective Study,” Circulation, 1999, 99(1):73-80. [PubMed 9884382]
  • 10. Guyatt GH, Akl EA, Crowther M, et al, “Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” Chest, 2012, 141(2 Suppl):7-47. [PubMed 22315257]
  • 11. Hull RD, Raskob GE, Rosenbloom D, et al, “Optimal Therapeutic Level of Heparin Therapy in Patients with Venous Thromboembolism,” Arch Intern Med, 1992, 152(8):1589-95. [PubMed 1497392]
  • 12. Jaff MR, McMurtry MS, Archer SL, et al, “Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement from the American Heart Association,” Circulation, 2011, 123(16):1788-830. [PubMed 21422387]
  • 13. Kearon C, Ginsberg JS, Julian JA, et al, “Comparison of Fixed-Dose Weight Adjusted Unfractionated Heparin and Low-Molecular-Weight Heparin for Acute Treatment of Venous Thromboembolism,” JAMA, 2006, 296(8):935-42. [PubMed 16926353]
  • 14. Klerk CP, Smorenburg SM, and Buller HR, “Thrombosis Prophylaxis in Patient Populations With a Central Venous Catheter: A Systematic Review,” Arch Intern Med, 2003, 163(16):1913-21. [PubMed 12963564]
  • 15. Levine GN, Bates ER, Blankenship JC, et al, “2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,” Circulation, 2011, 124(23):e574-651. [PubMed 22064601]
  • 16. Monagle P, Chan A, Goldenberg NA, et al, "Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition)," Chest, 2012, 141(2 Suppl):e737-801. [PubMed 22315277]
  • 17. Raschke RA, Reilly BM, Guidry JR, et al, “The Weight-Based Heparin Dosing Nomogram Compared With a “Standard Care” Nomogram: A Randomized Controlled Trial,” Ann Intern Med, 1993, 119(9):874-81.
  • 18. Savi P, Chong BH, Greinacher A, et al, “Effect of Fondaparinux on Platelet Activation in the Presence of Heparin-Dependent Antibodies: A Blinded Comparative Multicenter Study With Unfractionated Heparin,” Blood, 2005, 105(1):139-44. [PubMed 15388575]
  • 19. Sinnaeve PR, Alexander JH, Bogaerts K, et al,“Efficacy of Tenecteplase in Combination With Enoxaparin, Abciximab, or Unfractionated Heparin: One-Year Follow-Up Results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) Randomized Trial in Acute Myocardial Infarction,” Am Heart J, 2004, 147(6):993-8.
  • 20. Verma AK, Levine M, Shalansky SJ, et al, “Frequency of Heparin-Induced Thrombocytopenia in Critical Care Patients,” Pharmacotherapy, 2003, 23(6):745-53. [PubMed 12820817]
  • 21. Warkentin TE and Kelton JG, “Temporal Aspects of Heparin-Induced Thrombocytopenia,” N Engl J Med, 2001, 344(17):1286-92. [PubMed 11320387]
  • 22. Warkentin TE, "Heparin-Induced Thrombocytopenia: A Clinicopathologic Syndrome," Thromb Haemost, 1999, 82(2):439-47. [PubMed 10605735]
  • 23. Warkentin TE, Levine MN, Hirsch J, et al, “Heparin-Induced Thrombocytopenia in Patients Treated With Low-Molecular Weight Heparin or Unfractionated Heparin,” N Engl J Med, 1995, 332(20):1330-5. [PubMed 7715641]
  • 24. McLean J: The thromboplastic action of cephalin. Am J Physiol 1916; 41:250-257 [PDF]

 

  top |

 

 
© 2018 Prof. Dr. J. Braun